EQ-5D for the assessment of health-related quality of life and resource allocation in children: a systematic methodological review.

Value Health. 14: 1117-1129Longworth L Yang Y Young T et al.

Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey.

Health Technology Assessment.

Medical Device Innovation Consortium (MDIC). Patient centered benefit-risk project report: a framework for incorporating information on patient preferences regarding benefit and risk into regulatory assessments of new medical technology. Minneapolis, MN. 2015. https://mdic.org/wp-content/uploads/2015/05/MDIC_PCBR_Framework_Web.pdf. Accessed date: 14 May 2021.

de Bekker-Grob EW Berlin C Levitan B et al.

Giving patients’ preferences a voice in medical treatment life cycle: the PREFER public–private project.

Springer, Patient-Focused Drug Development Guidance: Collecting Comprehensive and Representative Input

US Food and Drug Administration.

Silver Spring, MDBrown L Lee T-h De Allegri M Rao K Bridges JF.

Applying stated-preference methods to improve health systems in sub-Saharan Africa: a systematic review.

Expert review of pharmacoeconomics & outcomes research. 17: 441-458Beckham SW Crossnohere NL Gross M Bridges JF.

Eliciting Preferences for HIV Prevention Technologies: A Systematic Review.

The Patient-Patient-Centered Outcomes Research. : 1-24Ozawa S Wonodi C Babalola O Ismail T Bridges J.

Using best-worst scaling to rank factors affecting vaccination demand in northern Nigeria.

Vaccine. 35: 6429-6437Ozawa S Grewal S Bridges JF.

Household size and the decision to purchase health insurance in Cambodia: results of a discrete-choice experiment with scale adjustment.

Applied health economics and health policy. 14: 195-204Hashim H Beusterien K Bridges JF Amos K Cardozo L.

Patient preferences for treating refractory overactive bladder in the UK.

International urology and nephrology. 47: 1619-1627Bridges JF Selck FW Gray GE McIntyre JA Martinson NA.

Condom avoidance and determinants of demand for male circumcision in Johannesburg, South Africa.

Health policy and planning. 26: 298-306Khadka J Kwon J Petrou S Lancsar E Ratcliffe J.

Mind the (inter-rater) gap. An investigation of self-reported versus proxy-reported assessments in the derivation of childhood utility values for economic evaluation: A systematic review.

Soc Sci Med. 240112543

Is It Time To Take a Harder Look at the QALY?.

Biotechnol Healthc. 5: 47-48Crossnohere NL Fischer R Lloyd A Prosser LA Bridges JFP.

Assessing the Appropriateness of the EQ-5D for Duchenne Muscular Dystrophy: A Patient-Centered Study.

Medical decision making: an international journal of the Society for Medical Decision Making. 41: 209-221Efthymiadou O Mossman J Kanavos P.

Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients.

Health Policy. 123: 159-165Patient-Focused Drug Development Draft Guidance: Methods to Identify What is Important to Patients

US Food and Drug Administration.

Silver Springs, MD

Health outcomes in economic evaluation: the QALY and utilities.

British Medical Bulletin. 96: 5-21Hauber AB Johnson FR Muhlbacher A Marshall D.

Maximum acceptale risk: Alternative measures for quantifying patients’ tolerance for theraputic benefit. International Society for Pharmacoeconomics and Outcomes Research.

Prauge, Czech Republic. Tsai JH Scheimann AO McCandless SE Strong TV Bridges JFP.

Caregiver priorities for endpoints to evaluate treatments for Prader-Willi syndrome: a best-worst scaling.

Journal of medical economics. 21: 1230-1237Tan Q Orsso CE Deehan EC et al.

Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review.

Obes Rev. 21: e12992Fehnel SE Brown TM Nelson L et al.

Development of the Hyperphagia Questionnaire for Use in Prader-Willi Syndrome Clinical Trials.

Value Health. 18: A25Dykens EM Maxwell MA Pantino E Kossler R Roof E.

Assessment of hyperphagia in Prader-Willi syndrome.

Obesity (Silver Spring). 15: 1816-1826

Kayadjanian N. PWS Clinical Trials Consortium Meets with FDA for a Critical Path Innovation Meeting: Foundation for Prader-Willi Research; 2019. https://www.fpwr.org/blog/pws-clinical-trials-consortium-meets-with-fda-for-a-critical-path-innovation-meeting Accessed 14 May 2021.

Albrecht GL Devlieger PJ.

The disability paradox: high quality of life against all odds.

Social Sci Med. 48: 977-988Simon NJ Richardson J Ahmad A et al.

Health utilities and parental quality of life effects for three rare conditions tested in newborns.

J Patient-Reported Outcomes. 3: 4Pyne JM Fortney JC Tripathi S Feeny D Ubel P Brazier J.

How bad is depression? Preference score estimates from depressed patients and the general population.

Health Serv Res. 44: 1406-1423Bridges JF Kinter ET Schmeding A Rudolph I Mühlbacher A.

Can patients diagnosed with schizophrenia complete choice-based conjoint analysis tasks?.

The Patient: Patient-Centered Outcomes Research. 4: 267-275

EuroQol–a new facility for the measurement of health-related quality of life.

Health Policy. 16: 199-208Perfetto EM Burke L Oehrlein EM Epstein RS.

Patient-focused drug development: a new direction for collaboration.

Med Care. 53: 9-17Hsu JC Wu H-C Feng W-C Chou C-H Lai EC-C Lu CY.

Disease and economic burden for rare diseases in Taiwan: A longitudinal study using Taiwan's National Health Insurance Research Database.

PloS One. 13e0204206Wästfelt M Fadeel B Henter JI.

A journey of hope: lessons learned from studies on rare diseases and orphan drugs.

J Intern Med. 260: 1-10Hollin IL Young C Hanson C Bridges JF Peay H.

Developing a patient-centered benefit-risk survey: a community-engaged process.

Value Health. 19: 751-757Miller JL Lynn CH Driscoll DC et al.

Nutritional phases in Prader-Willi syndrome.

Am J Med Genet. Part A. 155a: 1040-1049Tsai JH Janssen E Bridges JF.

Research as an event: a novel approach to promote patient-focused drug development.

Patient Preference Adherence. 12: 673-679

Models for count data with overdispersion.

Princeton. Hanley JA Negassa A Edwardes MDd Forrester JE.

Statistical analysis of correlated data using generalized estimating equations: an orientation.

Am J Epidemiol. 157: 364-375Bridges JF Tsai J-H Janssen E Crossnohere NL Fischer R Peay H.

How do members of the Duchenne and Becker muscular dystrophy community perceive a discrete-choice experiment incorporating uncertain treatment benefit? An application of research as an event.

Patient-Centered Outcomes Res. 12: 247-257Patient Preference Information–Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling

US Food and Drug Administration.

Silver Springs, MD

Aging, natural death, and the compression of morbidity.

N Engl J Med. 303: 130-135

The MaxDiff System Technical Paper. Sawtooth Software Technical Paper Series. 2020. https://sawtoothsoftware.com/uploads/sawtoothsoftware/originals/0114c81d-43ca-4339-bd30-fbf45146e8b2.pdf Accessed 14 May 2021.

Matza LS Boye KS Feeny DH Johnston JA Bowman L Jordan JB.

Impact of caregiver and parenting status on time trade-off and standard gamble utility scores for health state descriptions.

Health Qual Life Outcomes. 12: 48Chevreul K Berg Brigham K Clement MC Poitou C Tauber M

Economic burden and health-related quality of life associated with Prader-Willi syndrome in France.

J Intellectual Disabil Res. 60: 879-890Lopez-Bastida J Linertova R Oliva-Moreno J et al.

Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe.

Eur J Health Econ. 17: 99-108

How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy: Office of Health Economics.

EuroQol–a new facility for the measurement of health-related quality of life.

Health Policy. 16: 199-208

Improving decision analyses: parent preferences (utility values) for pediatric health outcomes.

J Pediatr. 155 (): 21-25Lloyd A Hodgkins P Sasane R et al.

Estimation of utilities in attention-deficit hyperactivity disorder for economic evaluations.

Patient-Centered Outcomes Res. 4: 247-257Prosser LA Hammitt JK Keren R.

Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children.

Pharmacoeconomics. 25: 713-726Lavelle TA Weinstein MC Newhouse JP Munir K Kuhlthau KA Prosser LA.

Parent Preferences for Health Outcomes Associated with Autism Spectrum Disorders.

PharmacoEconomics. 37: 541-551De Civita M Regier D Alamgir AH Anis AH FitzGerald MJ Marra CA.

Evaluating health-related quality-of-life studies in paediatric populations.

Pharmacoeconomics. 23: 659-685Prosser LA Ray GT O'Brien M Kleinman K Santoli J Lieu TA.

Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine.

Pediatrics. 113: 283-290Lee GM Salomon JA LeBaron CW Lieu TA.

Health-state valuations for pertussis: methods for valuing short-term health states.

Health Qual Life Outcomes. 3: 17Kuppermann M Nease Jr., RF Ackerson LM Black SB Shinefield HR Lieu TA

Parents' preferences for outcomes associated with childhood vaccinations.

Pediatr Infect Dis J. 19: 129-133Denis A Mergaert L Fostier C Cleemput I Simoens S.

A comparative study of European rare disease and orphan drug markets.

Health Policy. 97: 173-179Crossnohere NL Fischer R Crossley E Vroom E Bridges JF.

The evolution of patient-focused drug development and Duchenne muscular dystrophy.

Expert Rev Pharmacoecon Outcomes Res. 20: 57-68

Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerations.

Orphan Drugs Res Rev. 4: 1-9Schlander M Garattini S Holm S et al.

Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders.

J Comparative Effectiveness Res. 3: 399-422Ubel PA Loewenstein G Jepson C.

Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public.

Qual Life Res. 12: 599-607Masefield SC Prady SL Sheldon TA Small N Jarvis S Pickett KE.

The Caregiver Health Effects of Caring for Young Children with Developmental Disabilities: A Meta-analysis.

Matern Child Health J. 24: 561-574Lavelle TA D'Cruz BN Mohit B et al.

Family spillover effects in pediatric cost-utility analyses.

Appl Health Econ Health Policy. 17: 163-174Hyry HI Stern A Cox T Roos J.

Limits on use of health economic assessments for rare diseases.

Q J Med. 107: 241-245Norman R King MT Clarke D Viney R Cronin P Street D.

Does mode of administration matter? Comparison of online and face-to-face administration of a time trade-off task.

Qual Life Res. 19: 499-508Oppe M Rand-Hendriksen K Shah K Ramos-Goñi JM Luo N.

EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes.

Pharmacoeconomics. 34: 993-1004Bleichrodt H Johannesson M.

Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs.

J Health Econ. 16: 155-175Arnold D Girling A Stevens A Lilford R.

Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis.

BMJ. 339: b2688

Are QALYs based on time trade-off comparable? A systematic review of TTO methodologies.

Health Econ. 14: 39-53